RECRUITINGOBSERVATIONAL
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
A Retrospective (Non-interventional) Clinical Study on the First-line Maintenance Treatment of Peripheral T-cell Lymphoma (PTCL) With Chidamide.
About This Trial
The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.
Who May Be Eligible (Plain English)
Who May Qualify:
- (1) Age: 18 years and older; (2) Gender: Male/Female; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment.
Who Should NOT Join This Trial:
- (1) Patients with other types of lymphomas; (2) Pregnant women.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* (1) Age: 18 years and older; (2) Gender: Male/Female; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment.
Exclusion Criteria:
* (1) Patients with other types of lymphomas; (2) Pregnant women.
Treatments Being Tested
DRUG
chidamide
This subset of patients received chidamide as first-line maintenance therapy.
Locations (1)
Hematological Department, People's Hospital of Jiangsu Province
Nanjing, Jiangsu, China